Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
Status:
Withdrawn
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting
toxicity (DLT), and efficacy of a combination chemotherapy using CPT-11 and Paclitaxel in
pre-treated patients with metastatic gastric cancer. The usefulness of the this regimen is
evaluated by response rate, median survival time, and progression free survival.